Roche Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RHHBY research report →
Companywww.roche.com
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.
- CEO
- Thomas Schinecker
- IPO
- 2003
- Employees
- 103,249
- HQ
- Basel, CH
Price Chart
Valuation
- Market Cap
- $334.86B
- P/E
- 20.28
- P/S
- 4.25
- P/B
- 7.73
- EV/EBITDA
- 12.68
- Div Yield
- 2.99%
Profitability
- Gross Margin
- 73.53%
- Op Margin
- 31.32%
- Net Margin
- 20.94%
- ROE
- 41.23%
- ROIC
- 20.36%
Growth & Income
- Revenue
- $63.36B · 1.54%
- Net Income
- $12.88B · 55.61%
- EPS
- $2.02 · 55.53%
- Op Income
- $18.48B
- FCF YoY
- -10.85%
Performance & Tape
- 52W High
- $60.85
- 52W Low
- $37.51
- 50D MA
- $50.50
- 200D MA
- $48.48
- Beta
- 0.33
- Avg Volume
- 2.52M
Get TickerSpark's AI analysis on RHHBY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RHHBY Coverage
We haven't published any research on RHHBY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RHHBY Report →